Given the MMR gene-specific (MLH1, PMS2, MSH2, MSH6) differences regarding the age of cancer occurrence [3], it is essential to determine optimal screening protocols separately for each MMR protein abnormality detected by immunohistochemistry. Here, PMS2 is linked to cancer.